ARCA Awarded Method Patent for Gene Response Testing with Investigational Heart Failure Drug

Patent number 7,678,824, entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting," provides market exclusivity to ARCA for its approach to treating patients with heart failure.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.